A single-center, observational, retrospective, case control study of rituximab for the treatment of interstitial pneumonia associated with autoimmune features
Abstract
Background Patients with interstitial lung disease (ILD) and features of autoimmunity who do not meet the classification criteria for a specific autoimmune rheumatic disease are diagnosed with interstitial pneumonia with autoimmune features (IPAF). The treatment approach to ILD in this setting remains undefined. We conducted an observational retrospective study to examine the use of rituximab in IPAF. Methods Patients from the Mount Sinai Respiratory Institute Interstitial Lung Disease Registry were included if they met the 2015 classification criteria for IPAF and were treated with at least one dose of rituximab. Clinical improvement was defined as improvement in four domains after the use of rituximab including pulmonary function tests, CT chest findings, need for respiratory related hospitalization and survival. Results Of the 791 patients in the registry, 14 patients met the criteria for IPAF and received at least one dose of rituximab. Nineteen patients with IPAF were identified to serve as the control group. More patients in the rituximab group received immunosuppressive medications. The percentage of patients with improved, stable, or worsened pulmonary function tests was similar in both groups. Frequency of oxygen use, incidence of infection, respiratory related admissions and overall mortality was similar in both groups. Conclusion The majority of patients with IPAF receiving rituximab showed improvement or stability in their pulmonary function. Although both groups…
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Levofloxacin-Induced Tendon Rupture: A Case Report and Review of the Literature
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- Neuroprotective Effects of Epicatechin against Oxidative Stress-Induced Cognitive Impairment: A Systematic Review and Meta-Analysis
- Quality evaluation and in vitro interaction studies between levofloxacin 250mg and diclofenac sodium 50mg tablets
- Molecular Epidemiology of mcr-1 -Positive Polymyxin B-Resistant Escherichia coli Producing Extended-Spectrum β-Lactamase (ESBL) in a Tertiary Hospital in Shandong, China
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.